Diffuse large B-cell lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma (NHL) in adults characterized by a median age of presentation in the sixth decade of life (but also rarely occurring in adolescents and children) with the initial presentation being single or multiple rapidly growing masses (that may or may not be painful) in nodal or extranodal sites (such as thyroid, skin, breast, gastrointestinal tract, testes, bone, or brain) and that can be accompanied by symptoms of fever, night sweats and weight loss. DLBCL has an aggressive disease course, with the elderly having a poorer prognosis than younger patients, and with relapses being common.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Diffuse large B-cell lymphoma
- Therapeutic area
- Hematology
- diffuse large B-cell lymphoma
- DLBCL
- diffuse large B-cell lymphoma
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0018905
- Parent condition
- MONDO:0004949
Related records
Broader conditions (20)
- Aggressive B-cell non-Hodgkin lymphoma
- B-cell neoplasm
- B-cell non-Hodgkin lymphoma
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplasm of mature B-cells
- Neoplastic disease or syndrome
- Non-Hodgkin lymphoma
Narrower conditions (35)
- A53 diffuse large B-cell lymphoma
- ALK-positive large B-cell lymphoma
- BN2 diffuse large B-cell lymphoma
- Breast diffuse large B-cell lymphoma
- Colorectal diffuse large B-cell lymphoma
- Diffuse large B-cell lymphoma activated B-cell type
- Diffuse large B-cell lymphoma germinal center B-cell type
- Diffuse large B-cell lymphoma of the central nervous system
- Diffuse large B-cell lymphoma with chronic inflammation
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly
- EZB diffuse large B-cell lymphoma
- EZB-MYC- diffuse large B-cell lymphoma
- EZB-MYC+ diffuse large B-cell lymphoma
- Gastric diffuse large B-cell lymphoma
- Grade I lymphomatoid granulomatosis
- Grade II lymphomatoid granulomatosis
- Grade III lymphomatoid granulomatosis
- High grade B-cell lymphoma
- Intravascular large B-cell lymphoma
- Liver diffuse large B-cell lymphoma
Trials (971)
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
- 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Combination Study of CAR-T Therapy in r/r B-NHL
- A Compassionate Use (CU) Program of Odronextamab
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
- A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)
- A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
Approved drugs (8)
- Axicabtagene ciloleucel
- Epcoritamab
- Glofitamab
- Loncastuximab tesirine
- Polatuzumab vedotin
- Selinexor
- Tafasitamab
- Tisagenlecleucel
Drugs in development (223)
- ABC-294640 Phase 1
- Abexinostat Phase 2
- Acalabrutinib Phase 3
- Acetaminophen Phase 2
- Acyclovir sodium Phase 1
- Agatolimod sodium Phase 1
- Aldesleukin Phase 3
- Alemtuzumab Phase 2
- Alisertib Phase 1
- Alvocidib hydrochloride Phase 1
- AMG-319 Phase 1
- Apolizumab Phase 1
- Ascorbic acid Phase 2
- ASP-3026 Phase 1
- Atezolizumab Phase 2
- Avadomide Phase 1
- Avelumab Phase 3
- Azacitidine Phase 3
- AZD-5153 Phase 1
- Baltaleucel-T Phase 2
Other linked drugs (2)
- Mocetinostat
- Ocrelizumab